These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37758545)

  • 1. [Late steroid-induced ocular hypertension after intravitreal dexamethasone implants: A series of 20 cases].
    Billant J; Douma I; Agard E; Levron A; Bouvarel H; Leroux P; Badri Y; Dot C
    J Fr Ophtalmol; 2023 Nov; 46(9):1039-1046. PubMed ID: 37758545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of selective laser trabeculoplasty as an alternative in patients who developed ocular hypertension after intravitreal dexamethasone implants: a series of 35 eyes.
    Billant J; Agard E; Douma I; Levron A; Brunet O; Remignon CH; Sejournet L; Dot C
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3665-3673. PubMed ID: 35665853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LONG-TERM INCIDENCE AND RISK FACTORS OF OCULAR HYPERTENSION FOLLOWING DEXAMETHASONE-IMPLANT INJECTIONS: THE SAFODEX-2 STUDY.
    Rezkallah A; Mathis T; Abukhashabah A; Voirin N; Malclès A; Agard É; Lereuil T; Denis P; Dot C; Kodjikian L
    Retina; 2021 Jul; 41(7):1438-1445. PubMed ID: 33315814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular pressure fluctuation following intravitreal dexamethasone implant and incidence of secondary ocular hypertension: a Zambian perspective.
    Raj P; Kumar K; Balasubramaniam S; Geetha CS; Agarwal A
    Pan Afr Med J; 2021; 39():108. PubMed ID: 34512844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, Risk Factors, Treatment, and Outcome of Ocular Hypertension following Intravitreal Steroid Injections: A Comparative Study.
    Badrinarayanan L; Rishi P; George R; Isaac N; Rishi E;
    Ophthalmologica; 2022; 245(5):431-438. PubMed ID: 35468616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XEN Gel Stent to Treat Intraocular Hypertension After Dexamethasone-Implant Intravitreal Injections: 5 Cases.
    Rezkallah A; Mathis T; Denis P; Kodjikian L
    J Glaucoma; 2019 Jan; 28(1):e5-e9. PubMed ID: 30234749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular Hypertension Following Intravitreal Injection of 0.7mg Dexamethasone Implant versus 2mg Triamcinolone.
    Kuley B; Storey PP; Pancholy M; Obeid A; Murphy J; Goodman J; Wibbelsman TD; Regillo C; Chiang A
    Semin Ophthalmol; 2020 Feb; 35(2):141-146. PubMed ID: 32343619
    [No Abstract]   [Full Text] [Related]  

  • 8. Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice.
    Hemarat K; Kemmer JD; Porco TC; Eaton AM; Khurana RN; Stewart JM
    Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):680-685. PubMed ID: 30222802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
    Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION.
    Sudhalkar A; Kodjikian L; Chhablani J; Bhojwani D; Vasavada A
    Retina; 2018 Dec; 38(12):2343-2349. PubMed ID: 29016454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intraocular pressure elevation and intravitreal steroid implant injection: State of the art in 2023. Recommendations of the French Glaucoma Society and French Ophthalmology Society [French version]].
    Dot C; Poli M; Aptel F; Labbe A; Kodjikian L; Baillif S; Bodaghi B; Denis P
    J Fr Ophtalmol; 2023 Sep; 46(7):803-810. PubMed ID: 37481449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience.
    Monsellato R; Trovato E; Turchetti P; Forestiere M; Pistone A; De Sio S; Accetta L; Pacella F
    Clin Ter; 2020; 170(1):e11-e14. PubMed ID: 31850478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients.
    Choi W; Park SE; Kang HG; Byeon SH; Kim SS; Koh HJ; Lee S; Seong GJ; Kim CY; Kim M
    Br J Ophthalmol; 2019 Oct; 103(10):1380-1387. PubMed ID: 30523044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OBSERVED COMPLICATIONS FROM DEXAMETHASONE INTRAVITREAL IMPLANT FOR THE TREATMENT OF MACULAR EDEMA IN RETINAL VEIN OCCLUSION OVER 3 TREATMENT ROUNDS.
    Reid GA; Sahota DS; Sarhan M
    Retina; 2015 Aug; 35(8):1647-55. PubMed ID: 25932545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Late and sustained intraocular pressure elevation related to intravitreal anti-VEGF injections: Cases requiring filtering surgery (French translation of the article)].
    Leleu I; Penaud B; Blumen-Ohana E; Rodallec T; Adam R; Laplace O; Akesbi J; Nordmann JP
    J Fr Ophtalmol; 2018 Nov; 41(9):789-801. PubMed ID: 30348599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular hypertension and intravitreal steroids injections, update in 2023. French guidelines of the French glaucoma society and the French ophthalmology society.
    Dot C; Poli M; Aptel F; Labbe A; Kodjikian L; Baillif S; Bodaghi B; Denis P
    J Fr Ophtalmol; 2023 Oct; 46(8):e249-e256. PubMed ID: 37302867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.
    Chin EK; Almeida DRP; Velez G; Xu K; Peraire M; Corbella M; Elshatory YM; Kwon YH; Gehrs KM; Boldt HC; Sohn EH; Russell SR; Folk JC; Mahajan VB
    Retina; 2017 Jul; 37(7):1345-1351. PubMed ID: 27806001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant.
    Pérez-Sarriegui A; Casas-Llera P; Díez-Álvarez L; Contreras I; Moreno-López M; Figueroa MS; González-Martín-Moro J; Muñoz-Negrete FJ; Rebolleda G
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Dec; 93(12):580-585. PubMed ID: 30266279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population.
    Choi W; Bae HW; Choi EY; Kim M; Kim EW; Kim CY; Kim M; Seong GJ
    Br J Ophthalmol; 2020 Oct; 104(10):1423-1429. PubMed ID: 32071035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the safety zone for steroid-induced ocular hypertension induced by intravitreal dexamethasone implantation.
    Choi W; Bae HW; Shin HJ; Kim EW; Kim CY; Kim M; Seong GJ
    Br J Ophthalmol; 2022 Aug; 106(8):1150-1156. PubMed ID: 33737305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.